For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The CCTG Annual Spring Meeting of Participants will be held Friday, April 24 to Sunday, April 26 at the Chelsea Hotel in Toronto. Additionally, there are Workshops being held on Thursday, April 23, which are closed and by invitation only. These workshops will require a separate invitation and registration, and attendees invited to a Workshop in addition to the Spring Meeting must register for both.
CCTG would like to note, with sorrow, the recent death of Dr. Paul Goss and to recognize his contributions to the Group.
CCTG’s Tumour Tissue Data Repository (TTDR) has now moved into its new home at Kingston Health Sciences Centre (KHSC), a highly anticipated state-of-the-art space designed to support and advance the future of cancer research.
The TTDR expansion supports the group’s capacity for ongoing and new initiatives. The refurbished area includes a larger centralized capacity for genomic, transcriptomic and proteomic studies that will leverage expertise among member sites.
